Peanut Allergy clinical trials at UCLA
3 in progress, 0 open to eligible people
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
Sorry, in progress, not accepting new patients
This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
Los Angeles, California and other locations
Tezepelumab in Peanut Oral Immunotherapy
Sorry, not yet accepting patients
The proposed study is a proof-of-concept Phase 2, double-blind, randomized placebo-controlled clinical trial evaluating the safety and efficacy of tezepelumab and peanut Oral Immunotherapy (OIT) for the treatment of peanut allergy. Study participation is divided into 3 periods: (i) a monotherapy period comprised of injections of either Tezepelumab or placebo from week 0 to week 8, (ii) followed by a combination therapy period comprised of 56 weeks during which peanut OIT is built up and maintained, and (iii) a treatment withdrawal period comprised of 12 weeks. This study will enroll 62 peanut-allergic individuals from 12 to 55 years of age who experience dose-limiting symptoms to <=100 mg of peanut protein in a single dose (<= 144 mg cumulative dose) as assessed by DBPCFC. The primary objective is to determine whether 56 weeks of tezepelumab plus peanut OIT as compared to 56 weeks of placebo plus peanut OIT induces sustained unresponsiveness to peanut 12 weeks after stopping combination therapy.
Los Angeles, California and other locations
Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Sorry, in progress, not accepting new patients
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
Los Angeles, California and other locations
Our lead scientists for Peanut Allergy research studies include Maria I. Garcia-Lloret, MD.
Last updated: